1 Min Read
June 26 (Reuters) - Antisense Therapeutics Ltd
* ATl1102 for multiple sclerosis (MS) phase IIB IND application has been submitted to US Food And Drug ADMINISTRATION (Fda) for its review Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.